He has assigned his patent rights to the U.S.
(2 S,6 S)-hydroxynorketamine in the treatment of depression, anxiety, anhedonia, suicidal ideation,Īnd post-traumatic stress disorders. ( R,S)-ketamine metabolites in the treatment of depression and neuropathic pain and as a co-inventor on a patentĪpplication for the use of (2 R,6 R)-hydroxynorketamine and ( S)-dehydronorketamine, and other stereoisomeric dehydro and hydroxylated metabolites of Zarate is listed as a co-inventor on a patent for the use of ketamine in major depression and suicidal ideation as aĬo-inventor on a patent for the use of (2 R,6 R)-hydroxynorketamine, These organizations had no further role in study design in the collection,Īnalysis, or interpretation of data in the writing of the report or in the decision to submit the paper for publication.ĭr.
Zarate, and by a Brain andīehavior Mood Disorders Research Award to Dr. Institutes of Health (IRP-NIMH-NIH ZIAMH002857), by a NARSAD Independent Investigator Award to Dr. Ioline Henter (NIMH) provided excellent editorialįunding for this work was supported by the Intramural Research Program at the National Institute of Mental Health, National The authors thank the 7SE research unit and staff for their support. Specific considerations exist for research groups considering the ethics of research with suicidal individuals, 4, 5 we recommend the following general guidelines as We have experienced challenges in recruiting, consenting, and monitoring suicidal patients in clinical research. Receptor antagonist ketamine 3 as well as studies focused on the neurobiology of suicide, In our work with the N-methyl-D-aspartate (NMDA) Trials are essential in efforts to stabilize, and potentially decrease, the suicide rate. We agree that it is possible to safely perform clinical trials with suicidal participants and, furthermore, that such clinical Consequently, clinicians have few evidence-based treatments for the nine millionĪmericans who consider suicide each year. Or schizophrenia, further compounding health inequities. Trials for depression, so it is unclear which of our current medications are effective for treating these most vulnerable patients.įurthermore, suicidal patients are often excluded from non-depression clinical trials, including those for substance dependence, anxiety, In addition, as Iltis and colleagues highlight, suicidal individuals are typically excluded from clinical 1 Suicide rates in the United States have increased 33% sinceġ999, 2 partly due to the lack of appropriate treatments for suicidal individuals Ĭlozapine is the only medication approved for suicidal behavior and, as of the writing of this letter, no medications have been approved We applaud the recent report from Iltis and colleagues addressing the issue of excluding suicidal patients from clinical trials forĭepression.
Learn more about InventHelp's Invention Submission Services at. It is currently available for licensing or sale to manufacturers or marketers. The original design was submitted to the Denver sales office of InventHelp. Additionally, it is producible in design variations. The invention features a practical design that is easy to attach and use so it is ideal for parents with babies and children. As a result, it could help to minimize spills and it helps to keep babies and children occupied and happy while traveling in the car. In doing so, it can be used to hold food and snacks. The invention provides an effective way for children to utilize a plate while in a car seat. My design would eliminate the need to hold onto a traditional plate." 12, 2022 /PRNewswire/ - "I wanted to create a safe and convenient surface for babies and young children to hold snacks and food while riding in a car safety seat," said an inventor, from Aurora, Colo., "so I invented the KIDS CAR SEAT PLATE.
0 kommentar(er)
